talazoparib,enzalutamide
pfizer,astellas
['crpc', 'talapro 2']
#ascogu23 md neeraj agarwal talk about talapro 2: 1st phase 3 study to combine poly(adp-ribose) polymerase inhibitor tala + androgen receptor inhibitor enza, as 1l tx for mcrpc. median ibpfs was significantly improved in the tala + enza vs pbo + enza arm: not reached vs 21.9 mos 
Medical Oncologist at Centro Oncológico Integral, Hospital Ángeles Puebla. Cancer treatment must be personalized to the individual needs of the patient.